Top

Diabetologia

Published in:

01-06-2008 | Meta-Analysis

Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis

Authors: K. Jeitler, K. Horvath, A. Berghold, T. W. Gratzer, K. Neeser, T. R. Pieber, A. Siebenhofer

Published in: Diabetologia | Issue 6/2008

Abstract

Aims

We compared the effects of continuous subcutaneous insulin infusion (CSII) with those of multiple daily insulin (MDI) injections on glycaemic control, risk of hypoglycaemic episodes, insulin requirements and adverse events in type 1 and type 2 diabetes mellitus.

Methods

The electronic databases MEDLINE, EMBASE and CENTRAL were systematically searched for randomised controlled trials up to March 2007. A systematic review and meta-analysis were performed.

Results

Overall, 22 studies were included (17 on type 1 diabetes mellitus, two on type 2 diabetes mellitus, three on children). With regard to adults with type 1 diabetes mellitus, our meta-analysis found a between-treatment difference of −0.4% HbA_1c (six studies) in favour of CSII therapy. Available median rates of mild or overall hypoglycaemic events were comparable between the different interventions (1.9 [0.9–3.1] [CSII] vs 1.7 [1.1–3.3] [MDI] events per patient per week). Total daily insulin requirements were lower with CSII than with MDI therapy. In patients with type 2 diabetes mellitus, CSII and MDI treatment showed no statistically significant difference for HbA_1c. The incidence of mild hypoglycaemic events was comparable between the treatment groups. In adolescents with type 1 diabetes mellitus, glycated haemoglobin and insulin requirements were significantly lower in the CSII groups; no data were available on hypoglycaemic events. The only study performed in younger children did not provide enough data for conclusive inferences. No overall conclusions were possible for severe hypoglycaemia and adverse events for any of the different patient groups due to rareness of such events, different definitions and insufficient reporting.

Conclusions/interpretation

CSII therapy in adults and adolescents with type 1 diabetes mellitus resulted in a greater reduction of glycated haemoglobin, in adult patients without a higher rate of hypoglycaemia. No beneficial effect of CSII therapy could be detected for patients with type 2 diabetes mellitus.

Available only for authorised users

Pickup JC, Keen H, Parsons JA, Alberti KG (1978) Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1:204–207PubMed

Chantelau E, Spraul M, Muhlhauser I, Gause R, Berger M (1989) Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 32:421–426PubMedCrossRef

Guinn TS, Bailey GJ, Mecklenburg RS (1988) Factors related to discontinuation of continuous subcutaneous insulin-infusion therapy. Diabetes Care 11:46–51PubMedCrossRef

Guilhem I, Leguerrier AM, Lecordier F, Poirier JY, Maugendre D (2006) Technical risks with subcutaneous insulin infusion. Diabetes Metab 32:279–284PubMedCrossRef

Plotnick LP, Clark LM, Brancati FL, Erlinger T (2003) Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 26:1142–1146PubMedCrossRef

Richardson T, Kerr D (2003) Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 4:661–667PubMedCrossRef

Pickup J, Mattock M, Kerry S (2002) Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 324:705PubMedCrossRef

Retnakaran R, Hochman J, DeVries JH et al (2004) Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 27:2590–2596PubMedCrossRef

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896–1900PubMedCrossRef

10.

Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions 4.2.4 [updated March 2005]. In: The Cochrane Library (Issue 2) 2005. Wiley, Chichester

11.

Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef

12.

Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408–412PubMedCrossRef

13.

Bak JF, Nielsen OH, Pedersen O, Beck-Nielsen H (1987) Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients. Diabetes Res 6:155–158PubMed

14.

Bangstad HJ, Kofoed-Enevoldsen A, Dahl-Jorgensen K, Hanssen KF (1992) Glomerular charge selectivity and the influence of improved blood glucose control in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 35:1165–1169PubMedCrossRef

15.

Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Hanssen KF (1994) Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 37:483–490PubMedCrossRef

16.

Berg TJ, Nourooz-Zadeh J, Wolff SP, Tritschler HJ, Bangstad HJ, Hanssen KF (1998) Hydroperoxides in plasma are reduced by intensified insulin treatment. A randomized controlled study of IDDM patients with microalbuminuria. Diabetes Care 21:1295–1300PubMedCrossRef

17.

Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, Sandvik L (1985) Effects of intensified insulin treatment on various lesions of diabetic retinopathy. Am J Ophthalmol 100:644–653PubMed

18.

Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, Sandvik L (1988) Oscillatory potentials, macular recovery time, and diabetic retinopathy through 3 years of intensified insulin treatment. Ophthalmology 95:1358–1366PubMed

19.

Chiasson JL, Ducros F, Poliquin-Hamet M, Lopez D, Lecavalier L, Hamet P (1984) Continuous subcutaneous insulin infusion (Mill–Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy. Diabetes Care 7:331–337PubMedCrossRef

20.

Ciavarella A, Vannini P, Flammini M, Bacci L, Forlani G, Borgnino LC (1985) Effect of long-term near-normoglycemia on the progression of diabetic nephropathy. Diabetes Metab 11:3–8

21.

DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ, Dutch Insulin Pump Study Group (2002) A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 25:2074–2080PubMedCrossRef

22.

Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP (2000) Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care 23:1232–1235PubMedCrossRef

23.

Hanssen KF, Dahl-Jorgensen K, Brinchmann-Hansen O (1985) The influence of strict control on diabetic complications. Acta Endocrinol 272:57–60

24.

Hirsch IB, Bode BW, Garg S et al (2005) Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 28:533–538PubMedCrossRef

25.

Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O (1985) Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. BMJ 290:811–815PubMed

26.

Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF et al (1986) Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. BMJ 293:1195–1199PubMedCrossRef

27.

Dahl-Jorgensen K, Torjesen P, Hanssen KF, Sandvik L, Aagenaes O (1987) Increase in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional treatment. Diabetes 36:1–5PubMedCrossRef

28.

Dahl-Jorgensen K (1987) Near-normoglycemia and late diabetic complications. The Oslo Study. Acta Endocrinol 284:1–38

29.

Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandvik L, Aagenaes O (1988) Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo Study. Acta Endocrinol 117:19–25PubMed

30.

Home PD, Capaldo B, Burrin JM, Worth R, Alberti KG (1982) A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent diabetic subjects: improved control with CSII. Diabetes Care 5:466–471PubMedCrossRef

31.

Husted SE, Nielsen HK, Bak JF, Beck-Nielsen H (1989) Antithrombin III activity, von Willebrand factor antigen and platelet function in young diabetic patients treated with multiple insulin injections versus insulin pump treatment. Eur J Clin Invest 19:90–94PubMed

32.

Nosadini R, Velussi M, Fioretto P et al (1988) Frequency of hypoglycaemic and hyperglycaemic-ketotic episodes during conventional and subcutaneous continuous insulin infusion therapy in IDDM. Diabetes Nutr Metab 1:289–296

33.

Saurbrey N, Arnold-Larsen S, Moller-Jensen B, Kuhl C (1988) Comparison of continuous subcutaneous insulin infusion with multiple insulin injections using the NovoPen. Diabet Med 5:150–153PubMedCrossRef

34.

Schiffrin A, Belmonte MM (1982) Comparison between continuous subcutaneous insulin infusion and multiple injections of insulin. A one-year prospective study. Diabetes 31:255–264PubMedCrossRef

35.

Schmitz A, Christiansen JS, Christensen CK, Hermansen K, Mogensen CE (1989) Effect of pump versus pen treatment on glycaemic control and kidney function in long-term uncomplicated insulin-dependent diabetes mellitus (IDDM). Dan Med Bull 36:176–178PubMed

36.

Schottenfeld-Naor Y, Galatzer A, Karp M, Josefsberg Z, Laron Z (1985) Comparison of metabolic and psychological parameters during continuous subcutaneous insulin infusion and intensified conventional insulin treatment in type I diabetic patients. Isr J Med Sci 21:822–828PubMed

37.

Tsui E, Barnie A, Ross S, Parkes R, Zinman B (2001) Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 24:1722–1727PubMedCrossRef

38.

Ziegler D, Dannehl K, Koschinsky T, Toeller M, Gries FA (1990) Comparison of continuous subcutaneous insulin infusion and intensified conventional therapy in the treatment of type I diabetes: a two-year randomized study. Diabetes Nutr Metab 3:203–213

39.

Hoogma RP, Hammond PJ, Gomis R et al (2006) Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diab Med 23:141–147CrossRef

40.

Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV (2004) A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 27:1554–1558PubMedCrossRef

41.

Schiffrin A, Desrosiers M, Moffatt M, Belmonte MM (1983) Feasibility of strict diabetes control in insulin-dependent diabetic adolescents. J Pediatr 103:522–527PubMedCrossRef

42.

Schiffrin AD, Desrosiers M, Aleyassine H, Belmonte MM (1984) Intensified insulin therapy in the type I diabetic adolescent: a controlled trial. Diabetes Care 7:107–113PubMedCrossRef

43.

Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE (2005) A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 28:15–19PubMedCrossRef

44.

Herman WH, Ilag LL, Johnson SL et al (2005) A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 28:1568–1573PubMedCrossRef

45.

Raskin P, Bode BW, Marks JB et al (2003) Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 26:2598–2603PubMedCrossRef

46.

Siebenhofer A, Plank J, Berghold A et al (2006) Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev, Issue 2, Art. no.: CD003287. DOI 10.1002/14651858.CD003287.pub4

47.

Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N (2004) Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 8:1–171

48.

Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R (2003) Insulin pump therapy: a meta-analysis. Diabetes Care 26:1079–1087PubMedCrossRef

Title: Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis
Authors: K. Jeitler
K. Horvath
A. Berghold
T. W. Gratzer
K. Neeser
T. R. Pieber
A. Siebenhofer
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 6/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-008-0974-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis

Abstract

Aims

Methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 6/2008

No, the glycaemic target in the critically ill should not be ≤6.1 mmol/l

Identification of ALOX5 as a gene regulating adiposity and pancreatic function

Genetic analysis of recently identified type 2 diabetes loci in 1,638 unselected patients with type 2 diabetes and 1,858 control participants from a Norwegian population-based cohort (the HUNT study)

Diabetic podopathy—no thanks!

The relationship between admission blood glucose levels and hospital mortality

Evidence that autonomic mechanisms contribute to the adaptive increase in insulin secretion during dexamethasone-induced insulin resistance in humans

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page